FERNDALE, Michigan and NESS ZIONA, Israel, November 5 /PRNewswire/ -- Ferndale Laboratories Inc. and Foamix Ltd. announced today that the two companies have agreed to jointly develop non-steroidal foam for the treatment of atopic dermatitis.
According to this agreement, Foamix will be responsible for developing the foam formulations and Ferndale will have an option to continue definitive development and worldwide commercialization of the product. Additional terms were not disclosed.
Atopic dermatitis is very common in all parts of the world. It affects about 10% of infants and 3% of the total population in the United States. It can occur at any age but is most common in infants to young adults. The skin rash is very itchy and can be widespread, or limited to a few areas.
The development of the foam product will be directed to fortify the skin barrier by delivering a very high concentration of barrier-enhancing oils in an easy-to-apply formulation. Non-steroidal therapy is important for safe, long-term management of atopic dermatitis and the associated symptoms. Poor adherence to maintenance treatment for atopic dermatitis and parental anxiety about using topical steroids are common features seen among children with atopic dermatitis, and therefore, foams, which do not need extensive rubbing for spreading and absorption, offer an improved treatment modality for this disease.
"We believe that the Foamix foam offers an effective and convenient way to deliver treatment to patients with atopic dermatitis. These are often very young children who would benefit from the ease and comfort of use, combined with the efficacy of treatment," said James T. McMillan II, Chief Executive Officer of Ferndale.
"We are very proud to partner with an industry leader such as
Ferndale," said Foamix CEO Dr. Dov Tamarkin. "Foam offers properties that
increase usability, encourage compliance and boost user satisfaction.
Foamix foams are alcohol-free and the
|SOURCE Foamix Ltd|
Copyright©2007 PR Newswire.
All rights reserved